Erlotinib Versus Etoposide/Cisplatin With Radiation Therapy in Unresectable Stage III Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Phase 2 Trial
Year: 2020
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Institutions: Shandong Tumor Hospital, Shandong First Medical University, Huazhong University of Science and Technology, Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences, Fujian Medical University, Fujian Provincial Cancer Hospital, Zhengzhou University, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Zhejiang Cancer Hospital, Fudan University, Fudan University Shanghai Cancer Center, Sichuan University, Hebei Medical University, Fourth Hospital of Hebei Medical University, Air Force General Hospital PLA, Wuhan University, Zhongnan Hospital of Wuhan University, First Hospital of China Medical University, First Affiliated Hospital Zhejiang University, Zhejiang University, Guizhou Cancer Hospital, First Affiliated Hospital of Xiamen University, Peking University Cancer Hospital, Chinese PLA General Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3099105778